You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2024

Investigational Drug Information for Peficitinib

✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Peficitinib?

Peficitinib is an investigational drug.

There have been 14 clinical trials for Peficitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on August 8th 2014.

The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Psoriasis. The leading clinical trial sponsors are Astellas Pharma Inc, Astellas Pharma Global Development, Inc., and Astellas Pharma China, Inc.

There are forty-four US patents protecting this investigational drug and six hundred and thirty-four international patents.

Recent Clinical Trials for Peficitinib
A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese SubjectsAstellas Pharma China, Inc.Phase 1
A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)Astellas Pharma China, Inc.Phase 3
A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and MetforminAstellas Pharma IncPhase 1

See all Peficitinib clinical trials

Clinical Trial Summary for Peficitinib

Top disease conditions for Peficitinib
Top clinical trial sponsors for Peficitinib

See all Peficitinib clinical trials

US Patents for Peficitinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Peficitinib ⤷  Sign Up Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (Foster City, CA) ⤷  Sign Up
Peficitinib ⤷  Sign Up Kinase inhibitors Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB) ⤷  Sign Up
Peficitinib ⤷  Sign Up Substituted indazoles for treating tendon and/or ligament injuries NOVARTIS AG (Basel, CH) ⤷  Sign Up
Peficitinib ⤷  Sign Up Kinase inhibitors Respivert Limited (N/A) Topivert Pharma Limited (London, GB) ⤷  Sign Up
Peficitinib ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Peficitinib

Drugname Country Document Number Estimated Expiration Related US Patent
Peficitinib Argentina AR108926 2036-06-30 ⤷  Sign Up
Peficitinib Australia AU2017289158 2036-06-30 ⤷  Sign Up
Peficitinib Canada CA3029457 2036-06-30 ⤷  Sign Up
Peficitinib European Patent Office EP3478674 2036-06-30 ⤷  Sign Up
Peficitinib Spain ES2800339 2036-06-30 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.